Enhanced Response of Metformin towards the Cancer Cells due to Synergism with Multi-walled Carbon Nanotubes in Photothermal Therapy

Sweejiang Yoo1, Jin Hou2, Wenhui Yi3, Yingchun Li3, Weiping Chen3, Lingjie Meng3, Jinhai Si2 & Xun Hou1

Converging evidence from laboratory models pointed that the widely used antidiabetic drug metformin has direct effects on cancer cells. Thus far, relatively little attention has been addressed to the drug exposures used experimentally relative to those achievable clinically. Here, we demonstrated that metformin loaded on carbon nanotubes under near-infrared (NIR) irradiation led to the remarkably enhancement in response towards cancer cells. The dose of metformin has reduced to only 1/280 of typical doses in monotherapy (35: 10 000–30 000 µM) where the realization of metformin in conventional antidiabetic doses for cancer therapies becomes possible. The heat generated from carbon nanotubes upon NIR irradiation has mediated a strong and highly localized hyperthermia-like condition that facilitated the enhancement. Our work highlight the promise of using highly localized heating from carbon nanotubes to intensify the efficacy of metformin for potential cancer therapies.

A series of in vitro studies and xenograft models have evidenced that metformin has direct action on cancer cell growth and proliferation, where the effects are observed in a wide range of cancer cell lines, including breasts, colon, glioma, ovarian and endometrial1–4. Several studies have reported that the combination of metformin with chemotherapeutic drugs leads to an increased sensitivity to chemotherapy or a decreased drug dose for variety of cancer cell lines5,6. The very promising preclinical data have drawn much attention, so metformin is proposed as an anticancer agent in nondiabetic patients. However, people have deep concerns on its excessively high dose for anti-cancer therapy in comparison to that for type 2 diabetes mellitus (T2DM) treatment2,7. It has been demonstrated that the anticancer action in in vitro studies only prominent under the condition of high doses, typically from 10–30 mM, which is 3 orders higher than those in T2DM treatment (maximal plasma concentration approximately 10 to 30 µM)1,2,4,5,8–15. Such high doses of metformin cause fatal adverse effects, particularly metformin-associated lactic acidosis (MALA)2,11,12,16,17. Thus, it is of great importance to further enhance the efficacy of metformin in antancer treatment so as to lower the dose to avoid the fatal adverse effects. It has been widely accepted by the community that the current research goal is to evaluate metformin itself at conventional antidiabetic doses for possible use in oncology, particularly for indications that may require long-term administration, where its extensive safety record is of paramount importance18.

Intriguingly, the landmark study by Hirsch et al. has revealed that low doses of metformin (0.1 or 0.3 mM, ~10-fold higher than plasma concentrations of metformin in diabetic patients) selectively kill cancer stem cells (CSCs)14,19. CSCs are well resistant to chemotherapy and thus responsible for cancer relapse. Recently, Lee et al.
have reported that the responses of breast cancer cell to metformin are intensified under hyperthermia condition although the metformin concentration is only 30 μM which is as low as the plasma concentration of metformin in type 2 diabetes patients under metformin treatment. More recently, Eikawa et al. demonstrated that metformin exerts an immune-mediated antitumor effect by protecting CD8+ tumor-infiltrating lymphocytes (TILs) from apoptosis and inevitable functional exhaustion in the tumor microenvironment, which eventually results in tumor growth inhibition. The direct effect on CD8+ TILs are observable even at a physiologically relevant low concentration of 10 μM.

Following investigation of metformin at conventional antidiabetic doses for the antineoplastic activity, either in combination with other therapeutic method (hyperthermia/radiotherapy/chemotherapy) or prolong treatment time, indicated possible alternative to the aggressive dosing. As inspired by Lee’s work, we propose that the loading of metformin onto multi-walled carbon nanotubes (MWNTs-Met/PEG) under NIR irradiation would maximize the responses of cancer cells to metformin and reduce the dose accordingly. The photothermal and selective internalization of carbon nanotube inside the cells provides the highly localized heating and the function of targeting drug delivery.

Results and Discussion

The preparation of MWNTs-Met/PEG is illustrated in Fig. Illustration diagram of MWNTs-Met/PEG synthesis.

Figure 1. Illustration diagram of MWNTs-Met/PEG synthesis.

The ID/IG ratios for MWNTs-COOH, MWNTs-Met and MWNTs-Met/PEG are 0.55, 0.98 and 1.07, respectively. The higher ID/IG ratio of MWNTs-Met in comparison to MWNTs-COOH implies the successful grafting of metformin. The observed upshifting of G-band peak for MWNTs-Met/PEG in comparison to MWNTs-COOH and MWNTs-Met can be explained by the wrapping of DSPE-PEG (PEGylation) around the nanotube. The hydrophobic and van der Waals attraction between the polymers and graphite sheet increase the energy necessary for vibration to occur, which is reflected in the higher frequency of Raman peaks. The ratio between intensities of the disorder-induced D and G Raman band ID/IG is reciprocally related to the crystalline size (La), where

\[
L_a (nm) = \frac{(4.3 \pm 1.3) \times 10^4 \left( \frac{I_D}{I_G} \right)^{-1}}{E_i^4}
\]

(Ei is the excitation energy in eV). Therefore, higher amount of defects correlates to higher ID/IG ratio and reduces crystalline size. The monotonic decrease in La as shown in Table 1 indicates the introduction of modification. The reduced in La for MWNTs-Met implies the grafting of metformin due to higher ID/IG ratio. The change in ID/IG ratio in can be at least partly attributed to the covalent bonds between MWNTs-COOH and metformin. Interestingly, it is observed only a small decrease in La for MWNTs-Met/PEG. Covalent modification typically changes the position of D-band and ID/IG ratio whereas non-covalent modification could lead to small changes in D-band and ID/IG ratio due to (1) D-band from disaggregation carbon particles (2) field disturbance and physical strain in graphite skeleton.
The TEM images (Fig. 2c) show that the nanotubes are coated with PEG, which agree well with the FTIR and Raman results. The MWNTs-Met/PEG was soluble in water (125 µg·mL⁻¹) and the dispersion remained stable with no precipitation observed after centrifugation for 15 min at 3000 rpm (inset of Fig. 2c). To further interpret the surface modification of MWNTs, ζ-potential measurement was carried out (Table 2). MWNTs-COOH shows a negative potential of (−31.5 ± 0.6 mV) due to the presence of negative charged carboxyl groups. Meanwhile, MWNTs-Met shows a decreased ζ-potential of −27.1 ± 0.8 mV as the result of metformin grafting which

![Figure 2.](image)
is consistent with the FTIR findings. The PEGylation leads to the shift in $\zeta$ potential closer to neutral, from $-27.1 \pm 0.8$ mV to $-17.8 \pm 0.9$ mV, is proof of presence of a neutral charge shielding PEG layer on the surface of nanotubes that thought to mask the surface charge29–31.

The drug loading capability of MWNTs-Met/PEG was quantified by the thermo-gravimetric analysis (TGA) as shown in Fig. 2d. The weight loss was directly correlated to the increase of mass introduced to nanotubes at each step. Metformin experiences total weight loss at $700^\circ$C, while the PEG decomposes at 350–400°C. Hence, the point of near 750°C is chosen to determine the weight ratio of metformin and PEG. As can be seen in Fig. 2d, the MWNTs, MWNTs-Met and MWNTs-Met/PEG have shown weight loss of about 7.5%, 30.0% and 45.7%, respectively. Hence, the drug loading of metformin is 22.5%, while the PEG content is 15.7%. By applying the formula (Eqn. 2) introduced by Moaseri et al. in quantifying the functionalization yield using TGA results, the estimated amount of metformin per gram (mmol g$^{-1}$) is 1.742.$^{32–34}$

\[
\text{Drug loading of metformin for MWNTs – Met/PEG (mmol · g$^{-1}$)} = \frac{\text{Metformin (mmol)}}{\text{weight of carbon nanotubes (g)}}
\]

As shown in Fig. 2e, the temperature elevation is well correlated to the increase of power density and carbon nanotube concentration as expected. Upon NIR irradiation, nanotubes release a substantial vibrational energy due to optically stimulated electronics excitation and cause heating.$^{35}$ As can be seen in Fig. 2e, the MWNTs-Met/PEG solution quickly exceed 45°C under 2 W·cm$^{-2}$ NIR irradiation, indicating that the heat deposition from MWNTs-Met/PEG is sufficient to induce strong localized heating and pro-apoptosis.

By using confocal microscopy imaging (Fig. 3), we observed that upon exposure of MWNTs-Met/PEG to HepG2 cells, the MWNTs-Met/PEG was found to be internalized inside the cells within 3 hours after incubation. The green colour corresponded to the fluorescence labelling (Rhodamine 123) on carbon nanotubes. The cell membranes and nucleus were stained with CellMask Deep Red and DAPI, respectively. Apparently, the MWNTs-Met/PEG accumulated in the cytoplasm region. The enriched cellular uptake is correlated to the unique ability of carbon nanotube in crossing the membrane passively or translocation mechanism that is known as nanoneedle mechanism.$^{36}$

The cytotoxicity of metformin, MWNTs-COOH and MWNTs-Met/PEG toward HepG2 cells under NIR irradiation (2 W·cm$^{-2}$) were investigated using AO/EB staining. As can be seen in Fig. 4b, no apparent cytotoxicity was observed with HepG2 cells incubated with metformin (1 mM) without NIR irradiation. It is because the antiproliferation effect of metformin is well-evidenced to be prominent only under much higher doses, typically in range of several to tens of miliMolar. However, the cytotoxicity of metformin toward HepG2 cells is not evident under much lower doses, typically in range of several to tens of nM.$^{37}$ Moreover, the cancer cells are more susceptible to heat injury than normal cells due to specific biological features, reducing heat dissipating ability and lower interstitial pH.$^{38}$ Thus, it is possible to preferentially kill cancer cells rather normal cells via the localized heating.

Notably, the cell viability of HepG2 cells declined sharply to 5.7 ± 1.2% (P < 0.0001, n = 3) with MWNTs-Met/PEG upon NIR irradiation, 24% lower than that with MWNTs-COOH solely upon NIR irradiation. Besides introducing the heat injury to HepG2 cells directly which causes ~70% cells death, the excessive heat deposition from carbon nanotubes inside the cancer cells and the direct heating of the culturing solvent under 2 W·cm$^{-2}$ NIR irradiation have also mediated a strong local hyperthermia condition and a weak overall hyperthermia condition.$^{39}$ The localized heating inside cancer cells and the direct heating of the culturing solvent under 2 W·cm$^{-2}$ NIR irradiation also have mediated an extensive heat injury that causes ~70% cells death.

In subsequent, the power density was attenuated to 0.8 W·cm$^{-2}$ for 8 mins to contrast the metformin's effect through suppressing the contribution of heat injury. MTT assay and trypan blue exclusion assay were adopted here to evaluate the viability of HepG2 cells. From the MTT assay (Fig. 4c), the cell viability of MWNTs-Met/PEG, MWNTs-COOH and metformin declined to only 16.0 ± 2.2% (P < 0.0001, n = 4), 60.6 ± 6.5% (P < 0.01, n = 4) and 86.9 ± 5.6% (P > 0.05, n = 4), respectively. The MWNTs-Met/PEG shew 45% and 71% decrease in cell viability compared to MWNTs-COOH and carbon nanotubes. Whereas in the trypan blue exclusion assay (Fig. 4d), the cell viability of MWNTs-Met/PEG, MWNTs-COOH and metformin declined to only 22.7 ± 5.3% (P < 0.01, n = 3), 64.3 ± 5.1% (P < 0.01, n = 3) and 82.0 ± 5.2% (P > 0.05, n = 3), respectively. MWNTs-Met/PEG shew 41.6% and 59% decrease in cell viability compared to MWNTs-COOH and carbon nanotubes. There is no statistically significant difference regarding metformin solely under 0.8 W·cm$^{-2}$ (P > 0.05). The trend is in consistent with the MTT assay. In consider the above, it is evidenced that metformin with localized heat deposition from nanotubes (MWNTs-Met/PEG) has lead to significant enhancements.$^{40}$ The metformin concentration in the MWNTs-Met/PEG dispersion is only 35 µM, which 2 orders of magnitude lower than the typical effective doses (5–30 mM), for nomadic metformin in in vitro anti-cancer treatments according to the previous reports.

Next, we have loaded the metformin onto carbon nanotubes in two approaches, covalent bonding (MWNTs-Met/PEG) and physical absorption (MWNTs-Met$_{98}$/PEG). The covalent bonding has granted higher drug loading (35 µM; 1.742 mmol g$^{-1}$) whereas the physical absorption (25 µM; 1.254 mmol g$^{-1}$) has only ~72% of the drug loading of covalent bonding. Under the same condition (0.8 W·cm$^{-2}$, 8 mins) as shown in Fig. 4e,
the cell viability of MWNTs-Met/PEG and MWNTs-Met\textsubscript{PA}/PEG declined to 16 ± 2.2% (P < 0.0001, n = 4) and 23.6 ± 2.2% (P < 0.0001, n = 4), respectively. MWNTs-Met/PEG show 7.6% decrease in cell viability compared to MWNTs-Met\textsubscript{PA}/PEG. Apparently, the 7.6% decrement is attributed to the higher content of metformin grafted, evidencing the contribution of metformin and synergism effect.

Conventional dosing of metformin is sufficient to result in an indirect cytostatic effect on certain tumours that thrive in hyperinsulimic and hyperglycemic environment through the suppression of liver gluconeogenesis due to hepatocyte energy stress, even if metformin does not accumulate in neoplastic tissue. On contrary, if adequate drug levels are achieved in cancer cells that have intact mechanisms to cope with energetic stress, it will result in reduced cellular energy consumption via modulating the signalling pathways. It is expected to have important antiproliferation effect\textsuperscript{18}.

**Figure 3.** Confocal images of HepG2 cells with MWNTs-Met/PEG incubation (left) low magnification (right) high magnification. The nanotubes were found internalized and accumulated inside the cell about 3 hours after incubation.
To achieve sufficient drug level in neoplastic tissue for prominent antiproliferation effect, the metformin concentration used experimentally has far exceeded than those achievable clinically. The extreme dose is rarely in clinical setting and known to associate fatal adverse effect. Thus, the results obtained cannot be considered as an approximation of clinical use and directly extrapolated to potential effect in clinical trial39. It is paramount to achieve sufficient drug levels in neoplastic tissue to allow the clinical evaluation yet retains the administrated metformin concentration at the level of conventional antidiabetic dose.

As previously mentioned, conventional hyperthermia with prolongs heating time up to 6 h has result in observable enhancement in the metformin antiproliferation action even at the conventional diabetic dose8. Lee et al. concluded the heat-induced enhancement of metformin cytotoxicity is mediated by potentiation of AMPK activation. Hyperthermia has been demonstrated to activate AMPK and suppresses mTOR activity. Owing to the excellent photothermal and translocation behaviour of carbon nanotubes, we have introduced a short and highly localized heating to intensify the antiproliferation action of metformin at the conventional antidiabetic dose. The outcome is comparable to the condition of aggressive dosing in metformin monotherapy. The localized heating has the superiority in spatial confinement over conventional hyperthermia. Therefore, the temperature elevation could exceeds the safe upper limits of hyperthermia (42–43 °C) with minimal collateral tissue damage40. The significant synergistic effect observed in elevated temperature may possible due to AMPK activation and drug-heat interaction8, 41. In our model, the low dose with high spatial heating confinement minimizes the adverse effect and facilitates the possible use in clinical.

Conclusion
Although we are unable to conclude the mechanism for the enhancement effect under localized heating at the current stage, we have demonstrated the promise of using highly localized hyperthermia-like condition from carbon nanotube to intensify the efficacy of metformin and addressed the dilemma of aggressive dosing for the potential cancer therapies.
Experimental Section
Preparation and characterization of MWNT-Met/PEG. 35 mg of MWNTs were mildly oxidized by mixture of nitric acid and sulphuric acid (1:3 v/v) in sonication bath for 120 min at 50 °C. Then the mixture was filtered and washed to obtain filter cake of carboxylated MWNTs (MWNTs-COOH). MWNTs-COOH was diluted in 50 mL Morpholinoethanesulfonic acid Monohydrate buffer. 180 μL of EDAC and 0.2 g of N-Hydroxysuccinimide (NHS) were added into dispersion, followed by rhodamine 123 and 0.165 g of metformin hydrochloride in 4 hours later. The dispersion was then stirred overnight for 24 h under room temperature of 25 °C. The dispersion was filtered and washed to obtain MWNTs-Met filter cake. The filter cake was then re-dispersed in 30 ml of 0.4 g·L⁻¹ DSPE-PEG. The dispersion was placed in sonication bath for 30 min at 50 °C. Lastly, the dispersion was filtered and washed to obtain the final form of MWNTs-Met/PEG and dried overnight at 60 °C. For preparation of MWNTs-Met_p0/PEG, the method was identical to MWNTs-Met/PEG except that EDAC, NHS and rhodamine 123 were not added. IR spectra were conducted by using VERTEX 70 FT-IR spectrometer, Bruker Optics. Raman spectra were obtained by using LabRAM HR 800, Horiba JOBIN YVON (633 nm). The zeta potential measurements were conducted by using zeta potential analyser (Zetasizer Nano ZX90, Malvern). Visual characterization was conducted by using TEM JEM-2100, JEOL. TGA curves were conducted by using TGA/DSC, Mettler Toledo.

Ex Vitro Measurement of heating of MWNTs-Met/PEG solution by NIR radiation. The MWNTs-Met/PEG solution was irradiated by 808 nm NIR laser at 0.5 W·cm⁻² with tuneable power density up to 2.0 W·cm⁻². The laser beam was reflected with dielectric lens several times so that the beam was directed perpendicularly to the cell at direction of Z-axis. The temperature elevation was measured via thermocouple and data logging system from Omega. Care was taken to shelter the thermocouple from direct exposure to laser beam path to minimize any direct heating from laser.

Cell culture and cellular incubation with MWNTs-Met/PEG. The HepG2 cells were cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin in 24-well plates. The cells were seeded for 18/24 h before the incubation with MWNTs-Met/PEG at final concentration of 20 μg·mL⁻¹. The incubation was carried out at 37 °C and 5% CO₂ atmosphere.

In vitro photothermal therapy of HepG2 cells. The HepG2 cells with and without nanotubes incubation were subject to 808 nm NIR irradiation. To avoid contamination, the well plates cover was sealed during whole process of laser irradiation. The laser beam was reflected with 808 nm dielectric lens several times so that the beam was directed perpendicularly to well plates at direction of Z-axis. The exposure time was 5 min with power density of 2.0 W·cm⁻² and 8 min of 0.8 W·cm⁻², respectively. The beam size was ~1 cm, nearly fully covering the area of individual column of 24-well plates. To mimic the biological environment, the well plate was heated to 37 ± 1 °C and maintained over laser irradiation process by a custom-made temperature control system.

Acridine orange (AO) and ethidium bromide (EB) fluorescent assay for cell death. AO and EB staining was performed as described by Spector et al. HepG2 cells were cultured separately in 24-well plates and treated with the complex (metformin, MWNTs-COOH and MWNTs-Met/PEG) for 48 h, where PBS (10 mM) was used as solvent control. After laser excitation for 5 min (808 nm, 2.0 W·cm⁻²), the treated and untreated cells were incubated with acridine orange and ethidium bromide solution (1 part of 100 μg·mL⁻¹ each of acridine orange and ethidium bromide in PBS) and examined in a fluorescent microscope (Carl Zeiss, Jena, Germany) using a UV filter (450–490 nm). Three hundred cells per sample were counted, in triplicate, for each time point and scored as viable or dead, and if dead whether by apoptosis or necrosis as judged from the nuclear morphology and cytoplasmic organization.

MTT cell proliferation assay. The HepG2 cells were suspended in DMEM media and plated at a density of 5 × 10⁴ cells/well into a 96-well culture dish. After 24 h, the medium was replaced with DMEM in the presence or absence of complex (metformin, MWNTs-COOH, MWNTs-Met/PEG and MWNTs-Met_p0/PEG) for 24 h, followed by laser excitation for 8 min (808 nm, 0.8 W·cm⁻²). The viability of HepG2 cells were detected by a 3-(4,5-dimethylthiazol-2-yl)–2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay kit.

Trypan blue exclusion assay. The HepG2 cells were suspended in DMEM media and plated at a density of 2 × 10⁴ cells/well into a 24-well culture dish. After 24 h, the medium was replaced with DMEM in the presence or absence of complex (metformin, MWNTs-COOH and MWNTs-Met/PEG) for 24 h, followed by laser excitation for 8 min (808 nm, 0.8 W·cm⁻²). The viability of HepG2 cells were detected by trypan blue and direct cell counting using hemacytometer.

Confocal imaging. HepG2 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum and penicillin-streptomycin 1%. The incubations of MWNTs-Met/PEG with HepG2 cells were carried out on 3.5 mm plates, with the cells having been seeded for 24 hours before MWNTs-Met/PEG was added. The incubations were carried out at 37 °C in 5% CO₂ for 24 hours. After incubation, the CellMask Deep Red was added and the cells were washed three times with phosphate-buffered solution. The cells were imaged by a scanning confocal fluorescence microscope.

Statistics. All data are presented as the mean ± standard error of the mean (s.e.m.). Data presented were analysed with unpaired t-tests. Statistical analysis was performed in Graphpad Prism 6.0 and P < 0.05 was considered as statistical significant in all analyses.
Reference

1. Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N. & Pollak, M. Metformin Is an AMP Kinase-Dependent Growth Inhibitor for Breast Cancer Cells. *Cancer Research* **66**, 10269–10273 (2007).

2. Sahra, I. B., Le Marchand-Brustel, Y., Tanti, J.-F. & Bost, F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? *Molecular cancer therapeutics* **9**, 1092–1099 (2010).

3. Goodwin, P. J., Ligibel, J. A. & Stambolic, V. Metformin in breast cancer: time for action. *Journal of clinical oncology* **27**, 3271–3273 (2009).

4. Dowling, R. J., Zakikhani, M., Fantus, I. G., Pollak, M. & Sonenberg, N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. *Cancer Research* **67**, 10804–10812 (2007).

5. Liu, H. et al. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. *Anticancer Research* **32**, 1627–1637 (2012).

6. Iliopoulos, D., Hirsch, H. A. & Struhl, K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. *Cancer research* **71**, 3196–3201 (2011).

7. Cazzaniga, M., Bonanni, B., Guerrieri-Gonzaga, A. & Decensi, A. Is it time to test metformin in breast cancer clinical trials? *Cancer Epidemiology, Biomarkers & Prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology* **18**, 701–705 (2009).

8. Lee, H. et al. Response of Breast Cancer Cells and Cancer Stem Cells to Metformin and Hyperthermia Alone or Combined. *PloS One* **9**, e87979 (2014).

9. Menendez, J. A. Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena. *Cell Cycle* **9**, 1057–1064 (2010).

10. Bailey, C. J. & Turner, R. C. Metformin. *New England Journal of Medicine* **354**, 574–579, doi:10.1056/NEJM200612283340906 (1996).

11. Liu, H. Metformin-Associated Lactic Acidosis following Intentional Overdose Successfully Treated with Tris-Hydroxymethyl Aminomethane and Renal Replacement Therapy. *Case Reports in Nephrology* **2012**, 671595–671595 (2012).

12. Lalai, J. D. & Race, J. M. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of ‘metformin-associated lactic acidosis’. *Diabetes Obesity & Metabolism* **3**, 195–201 (2001).

13. Liu, B. et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. *Cell Cycle* **8**, 2031–2040 (2009).

14. Hirsch, H. A., Iliopoulos, D., Tischis, P. N. & Struhl, K. Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission. *Cancer Research* **69**, 7507–7511 (2009).

15. Alimova, I. N. et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. *Cell Cycle* **8**, 909–915, doi:10.4161/cc.8.6.9733 (2009).

16. Dell’Aglio, D. M. et al. Acute Metformin Overdose: Examining Serum pH, Lactate Level, and Metformin Concentrations in Survivors Versus Non-survivors: A Systematic Review of the Literature. *Annals of Emergency Medicine* **54**, 818–823, doi:10.1016/j.annemergmed.2009.04.023 (2009).

17. Pernicova, I. & Korbonits, M. Metformin-mode of action and clinical implications for diabetes and cancer. *Nature Reviews Endocrinology* **10**, 143–156, doi:10.1038/nrendo.2013.236 (2014).

18. Pollak, M. N. Investigating Metformin for Cancer Prevention and Treatment: Th3 End of the Beginning. *Cancer Discovery* **2**, 778–799, doi:10.1158/2159-8290.cd-12-0263 (2012).

19. Hirsch, H. A., Iliopoulos, D. & Struhl, K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. *Proceedings of the National Academy of Sciences of the United States of America* **110**, 972–977 (2013).

20. Eikawa, S. et al. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. *Proceedings of the National Academy of Sciences of the United States of America* **112**, 1809–1814 (2015).

21. Song, C. W. et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. *Scientific Reports* **2**, 282–282 (2012).

22. Fasih, A., Elbaz, H. A., Hüttmann, M., Konski, A. A. & Zieglshe, S. P. Radiosensitization of Pancreatic Cancer Cells by Metformin through the AMPK Pathway. *Radiation Research* **182**, 50–59 (2014).

23. Iyer, A. K., Khaled, G., Fang, J. & Maeda, H. Exploiting the enhanced permeability and retention effect for tumor targeting. *Drug Discovery Today* **11**, 812–818 (2006).

24. O’Connell, M., Wisdom, J. A., Dai, H. & Gray, H. B. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. *Proceedings of the National Academy of Sciences of the United States of America* **102**, 11606–11605 (2005).

25. Simani, V. A. et al. Aqueous Dispersions of Single-wall and Multwall Carbon Nanotubes with Designed Amphiphilic Poylactons. *Journal of the American Chemical Society* **127**, 3463–3475 (2005).

26. Liu, A., Homma, I., Ichihara, M. & Zhou, H. Poly(acrylic acid)-wrapped multi-walled carbon nanotubes composite solubilization in water: Definitive spectroscopic properties. *Nanotechnology* **17**, 2845–2849 (2006).

27. Cançado, L. G. et al. Quantifying defects in graphene via Raman spectroscopy at different excitation energies. *Nanotechnology* **21**, 3190 (2010).

28. Fang, M., Wang, K., Lu, H., Yang, Y. & Nett, S. Covalent polymer functionalization of graphene nanosheets and mechanical properties of composites. *Journal of Materials Chemistry* **19**, 7098–7105 (2009).

29. Verhoeef, J. J. F. & Anchordoguy, T. J. Questioning the use of PEGylation for drug delivery. *Drug Delivery and Translational Research* **3**, 499–503, doi:10.1080/21596963.2013.817653 (2013).

30. deKrafft, K. E., Boyle, W. S., Burkh, L. M., Zhou, O. Z. & Lin, W. Ze- and Hf-based nanoscale metal-organic frameworks as contrast agents for computed tomography. *Journal of Materials Chemistry* **22**, 18139–18144, doi:10.1039/C2JM2299D (2012).

31. Owens, D. E., Eby, J. K., Jian, Y. & Peppas, N. A. Temperature-responsive polymer–gold nanocomposites as intelligent therapeutic systems. *Journal of Biomedical Materials Research Part A* **83A**, 692–695, doi:10.1002/jbm.a.31284 (2007).

32. Amirzadeh, A. et al. Transformer oil based multi-walled carbon nanotube–hexylamine coolant with optimized electrical, thermal and rheological enhancements. *Advances in Materials Research* **5**, 107222–107236 (2015).

33. Moaseri, E., Maghrebi, M. & Baniamad, M. Improvements in mechanical properties of carbon fiber-reinforced epoxy composites: A microwave-assisted approach in functionalization of carbon fiber via diamines. *Materials & Design* **55**, 644–652 (2014).

34. Amirzadeh, A. et al. Microwave-assisted direct coupling of graphene nanoplatelets with poly ethylene glycol and 4-phenylazophenol molecules for preparing stable-collodial system. *Colloids & Surfaces A: Physicochemical & Engineering Aspects* **457**, 131–141 (2015).

35. Kam, N. W. S. & Dai, H. Carbon nanotubes as intracellular protein transporters: generality and biological functionality. *Journal of the American Chemical Society* **127**, 6021–6026 (2005).

36. Pantarotto, D., Briand, J. P., Prato, M. & Bianco, A. Translocation of bioactive peptides across cell membranes by carbon nanotubes. *Chemical Communications* **10**, 16–17 (2004).

37. Zhou, M. et al. Doxorubicin-Loaded Single Wall Nanotube Thermo-Sensitive Hydrogel for Gastric Cancer Chemo-Photothermal Therapy. *Advanced Functional Materials* **25**, 4730–4739, doi:10.1002/adfm.201501434 (2015).

38. Nikfarjam, M., Murdialdharan, V. & Christophi, C. Mechanisms of Focal Heat Destruction of Liver Tumors. *Journal of Surgical Research* **127**, 208–223 (2005).
39. Stambolic, V., Woodgett, J. R., Fantus, I. G., Pritchard, K. I. & Goodwin, P. J. Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor? *Breast Cancer Research and Treatment* **114**, 387–389, doi:10.1007/s10549-008-0015-4 (2009).
40. Hahn, G. M. Potential for Therapy of Drugs and Hyperthermia. *Cancer Research* **39**, 2264–2268 (1979).
41. Issels, R. Hyperthermia adds to chemotherapy, *European Journal of Cancer* **44**, 2546–2554 (2008).
42. Spector, D. L., Goldman, R. D. & Leinwand, L. A. e. *Cell: A Laboratory Manual. Volume 3: Subcellular Localization of Genes and Their Products.* (Cold Spring Harbor Laboratory Press, 1998).

Acknowledgements

We are grateful to Natural Science Foundation of China (No. 61275179, and 60970815), Fundamental Funds for the Central Universities (No. xjc2015112) and Natural Science Basic Research Plan in Shaanxi Province of China (Program No. 2016JM8047). The TEM work was done at International Center for Dielectric Research (ICDR), Xi'an Jiao Tong University, Xi'an, China. The authors also thank Mr. C.H. Ma for his help in using TEM.

Author Contributions

J.H., W.Y. and M.L. conceived and designed the experiment. S.Y. and W.Y. co-wrote the paper. S.Y., J.H., W.C. and Y.L. worked on material synthesis and analysis. X.H. and J.S. advised the study. W.Y. managed the research team. S.Y. and J.H. contributed equally to this work.

Additional Information

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017